ClinicalTrials.gg

Program

SYH2070

A development code. Also written as “SYH2070 injection dose1”, “SYH2070 injection dose2” and “SYH2070 injection”.

Its studies are mostly in Homozygous Familial Hypercholesterolemia · Hyperlipoproteinemia Type II, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since May 9, 20263 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group33 open or runningphase 2since May 9, 2026Nov 17, 2025Apr 30, 2027phase 2 · NCT07695597

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2025First study: phase 1 study in Healthy Subjects (HS)First studyNCT07241923 · 48 planned · China
  2. May 9, 2026Phase 2 study in Diagnosed With HoFHPhase 2 reachedNCT07591298 · 18 planned · China
  3. Jul 6, 2026Phase 2 study in Hyperlipoproteinemia Type IINCT07695597 · 240 planned · China

Ahead

  1. Nov 1, 2026Primary completion: phase 1 study in Healthy Subjects (HS)NCT07241923
  2. Apr 30, 2027Primary completion: phase 2 study in Hyperlipoproteinemia Type IINCT07695597
  3. Sep 16, 2027Primary completion: phase 2 study in Diagnosed With HoFHNCT07591298

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07695597Hyperlipoproteinemia Type II · China2RecruitingApr 30, 2027240
NCT07591298Diagnosed With HoFH · China2RecruitingSep 16, 202718
NCT07241923Healthy Subjects (HS) · China1RecruitingNov 1, 202648

How it is read

Names in the registry

  • “SYH2070 injection dose1”, 1 entry
  • “SYH2070 injection dose2”, 1 entry
  • “SYH2070”, 1 entry
  • “SYH2070 injection”, 1 entry

Codes read as this program: SYH2070.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.